Clinical Pharmacy Specialist – Hematology/Oncology
Froedtert & the Medical College of Wisconsin Cancer Center
Clinical Assistant Professor
Medical College of Wisconsin School of Pharmacy
Carolyn Oxencis, PharmD, BCOP is a Hematology/Oncology Clinical Pharmacist at the Froedtert and the Medical College of Wisconsin Clinical Cancer Center. She received her Doctor of Pharmacy degree from the University of Iowa College of Pharmacy and completed a PGY1 Pharmacy Practice Residency at Froedtert Hospital. Dr. Oxencis was a Board Certified Pharmacotherapy Specialist from 2010–2017 and is currently a Board Certified Oncology Pharmacist.
Dr. Oxencis joined the Medical College of Wisconsin School of Pharmacy in October 2016 as a Clinical Assistant Professor. Her role at the school includes serving as Course Director for the Hematology/Oncology Pharmacotherapy course, as well as precepting pharmacy students during their introductory practice and advanced experiential rotations. Additionally, Dr. Oxencis has precepted PGY1 and PGY2 residents for over a decade. Her professional interests include hematology, oncology, interprofessional education, research, and academia; her research interests include pharmacogenomics, biomarkers, biosimilars, cardiotoxicity of anticancer treatments, patient-reported outcomes, and digiceuticals.
Dr. Oxencis is a member of the ASHP Council on Therapeutics and is Immediate-Past Chair of the ASHP Section of Clinical Specialists and Scientists Section Advisory Group on Emerging Sciences. She also serves as Immediate-Past Chair of the Hematology Oncology Pharmacy Association (HOPA) Needs Assessment Committee. Dr. Oxencis was the recipient of an ASHP Best Practice Award in 2007 for her work on admission medication reconciliation and discharge transitions of care.
Expertise: Dr. Oxencis has an active clinical practice site and 5+ years of experience providing education on ICPI to patients and their families, as well as collaborating with the interprofessional team on monitoring and treating adverse effects of these medications. She has served as a speaker and education chair for multiple ASHP Midyear Clinical Meeting education sessions on the topic of immuno-oncology. Most recently Dr. Oxencis co-presented “A Whole New World: A Case-Based Approach to Managing CAR-T Cell Therapy and Immunotherapy Toxicities” at MCM 2018, and will be chairing “Critical Skills: A Case-Based Approach to Immunotherapy Induced Medical Emergencies in Non-Oncology Settings” at MCM 2019.
Disclosure: NO DISCLOSURE INFORMATION SUBMITTED